Caxton Associates LP Buys New Position in Amedisys, Inc. (NASDAQ:AMED)

Caxton Associates LP bought a new stake in shares of Amedisys, Inc. (NASDAQ:AMEDGet Rating) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 9,962 shares of the health services provider’s stock, valued at approximately $1,047,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Swiss National Bank increased its holdings in shares of Amedisys by 7.2% in the first quarter. Swiss National Bank now owns 77,100 shares of the health services provider’s stock valued at $13,284,000 after purchasing an additional 5,200 shares during the period. Field & Main Bank increased its holdings in shares of Amedisys by 17.7% in the second quarter. Field & Main Bank now owns 665 shares of the health services provider’s stock valued at $70,000 after purchasing an additional 100 shares during the period. Leeward Investments LLC MA acquired a new position in shares of Amedisys in the second quarter valued at about $9,435,000. Virtu Financial LLC acquired a new position in shares of Amedisys in the second quarter valued at about $412,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in shares of Amedisys in the first quarter valued at about $535,000. 93.36% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on AMED shares. Oppenheimer cut their price objective on Amedisys from $175.00 to $145.00 and set an “outperform” rating on the stock in a report on Friday, October 28th. Truist Financial lowered their target price on Amedisys from $140.00 to $130.00 and set a “buy” rating on the stock in a research note on Friday, October 28th. Royal Bank of Canada lowered their target price on Amedisys from $165.00 to $139.00 and set an “outperform” rating on the stock in a research note on Monday, October 31st. UBS Group lowered their target price on Amedisys to $88.00 in a research note on Friday, November 4th. Finally, Stephens lowered their target price on Amedisys from $122.00 to $106.00 and set an “equal weight” rating on the stock in a research note on Friday, November 11th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $136.13.

Amedisys Stock Performance

NASDAQ AMED opened at $87.07 on Friday. The company has a market cap of $2.83 billion, a PE ratio of 23.47, a price-to-earnings-growth ratio of 2.12 and a beta of 0.94. The stock’s 50 day simple moving average is $92.34 and its 200-day simple moving average is $109.11. Amedisys, Inc. has a 1-year low of $83.00 and a 1-year high of $179.91. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.06 and a quick ratio of 1.06.

Amedisys (NASDAQ:AMEDGet Rating) last released its earnings results on Wednesday, October 26th. The health services provider reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.24 by ($0.09). The firm had revenue of $557.99 million during the quarter, compared to analysts’ expectations of $579.30 million. Amedisys had a net margin of 5.45% and a return on equity of 16.00%. The business’s revenue was up .8% compared to the same quarter last year. During the same quarter last year, the business earned $1.53 EPS. As a group, equities research analysts anticipate that Amedisys, Inc. will post 4.84 EPS for the current fiscal year.

Amedisys Profile

(Get Rating)

Amedisys, Inc engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, and Personal Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness.

See Also

Want to see what other hedge funds are holding AMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amedisys, Inc. (NASDAQ:AMEDGet Rating).

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.